carnitine has been researched along with Diabetic Angiopathies in 10 studies
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results demonstrated that the biomarker panels consisted of specific amino acids and acylcarnitines which could reflect the metabolic variations among the different stages of diabetes and might be useful for the differential diagnosis of prediabetes, overt diabetes and diabetic complications." | 8.02 | Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications. ( Hu, R; Li, X; Li, Y; Liang, Y; Liu, Y; Xu, W, 2021) |
| " The authors, on the basis of recent studies demonstrating the rheological and vasoactive as well as metabolic activities of levocarnitine propionyl, have decided to use this substance in the treatment of arteriopathics affected by intermittent claudication." | 5.07 | Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. ( Coto, V; D'Alessandro, L; Grattarola, G; Imparato, L; Lingetti, M; Mancini, M; Nolfe, G; Rengo, F, 1992) |
| "Our results demonstrated that the biomarker panels consisted of specific amino acids and acylcarnitines which could reflect the metabolic variations among the different stages of diabetes and might be useful for the differential diagnosis of prediabetes, overt diabetes and diabetic complications." | 4.02 | Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications. ( Hu, R; Li, X; Li, Y; Liang, Y; Liu, Y; Xu, W, 2021) |
| "Seventy-four patients with NIDDM-associated PAD were treated with PLC (2 g/day) or placebo for 12 months." | 2.72 | Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. ( Gabriella, C; Gea, OC; Giuseppe, M; Giuseppe, P; Luigi, DP; Margherita, F; Massimiliano, A; Roberto, F; Santo, SS; Sergio, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Li, Y | 1 |
| Liang, Y | 1 |
| Hu, R | 1 |
| Xu, W | 1 |
| Liu, Y | 1 |
| Santo, SS | 1 |
| Sergio, N | 1 |
| Luigi, DP | 1 |
| Giuseppe, M | 1 |
| Margherita, F | 1 |
| Gea, OC | 1 |
| Roberto, F | 1 |
| Gabriella, C | 1 |
| Giuseppe, P | 1 |
| Massimiliano, A | 1 |
| Celik, T | 1 |
| Kursaklioglu, H | 1 |
| Iyisoy, A | 1 |
| Jata, B | 1 |
| Stevens, MJ | 1 |
| Feldman, EL | 1 |
| Greene, DA | 1 |
| Costanza, G | 1 |
| Di Salvo, A | 1 |
| Barone, G | 1 |
| Verruso, G | 1 |
| Zamueli, M | 1 |
| Marchese, G | 1 |
| Coker, M | 1 |
| Coker, C | 1 |
| Darcan, S | 1 |
| Can, S | 1 |
| Orbak, Z | 1 |
| Gökşen, D | 1 |
| Williamson, JR | 1 |
| Arrigoni-Martelli, E | 1 |
| Coto, V | 1 |
| D'Alessandro, L | 1 |
| Grattarola, G | 1 |
| Imparato, L | 1 |
| Lingetti, M | 1 |
| Mancini, M | 1 |
| Nolfe, G | 1 |
| Rengo, F | 1 |
| Greco, AV | 1 |
| Mingrone, G | 1 |
| Bianchi, M | 1 |
| Ghirlanda, G | 1 |
| Tahiliani, AG | 1 |
| McNeill, JH | 1 |
3 reviews available for carnitine and Diabetic Angiopathies
| Article | Year |
|---|---|
The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects.
Topics: Aldehyde Reductase; Animals; Carnitine; Cells; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 1995 |
The roles of glucose-induced metabolic hypoxia and imbalances in carnitine metabolism in mediating diabetes-induced vascular dysfunction.
Topics: Animals; Blood Glucose; Carnitine; Cell Hypoxia; Diabetic Angiopathies; Humans; NAD | 1992 |
Diabetes-induced abnormalities in the myocardium.
Topics: Adenosine Triphosphatases; Animals; Blood Glucose; Calcium; Carbohydrate Metabolism; Cardiomyopathie | 1986 |
5 trials available for carnitine and Diabetic Angiopathies
| Article | Year |
|---|---|
Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD.
Topics: Aged; Aldehydes; Ankle; Blood Glucose; Blood Pressure; Brachial Artery; Carnitine; Cholesterol, LDL; | 2006 |
[Comparison between L-propionyl carnitine and physical-rehabilitative exercise in diabetics with obliterative arteriopathy of the legs (Fontaine's stage IIa)].
Topics: Arterial Occlusive Diseases; Cardiotonic Agents; Carnitine; Diabetic Angiopathies; Female; Humans; L | 1999 |
Carnitine metabolism in diabetes mellitus.
Topics: Adolescent; Adult; Carnitine; Child; Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Angiopath | 2002 |
Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo.
Topics: Administration, Oral; Aged; Analysis of Variance; Arterial Occlusive Diseases; Arteriosclerosis; Car | 1992 |
Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo.
Topics: Administration, Oral; Aged; Analysis of Variance; Carnitine; Diabetic Angiopathies; Double-Blind Met | 1992 |
2 other studies available for carnitine and Diabetic Angiopathies
| Article | Year |
|---|---|
Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications.
Topics: Amino Acids; Carnitine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metabolomics; Pred | 2021 |
Metabolic agents in the management of diabetic coronary patients: a new era.
Topics: Carnitine; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Dichloroacetic Acid; Enzyme I | 2008 |